+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Dacomitinib"

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Thumbnail Image

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • January 2026
  • 186 Pages
  • Global
From
EGFRm-Positive NSCLC Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Thumbnail Image

EGFRm-Positive NSCLC Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • March 2025
  • 89 Pages
  • Global
From
Non-Small Cell Lung Cancer (NSCLC) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034 - Product Thumbnail Image

Non-Small Cell Lung Cancer (NSCLC) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034

  • Report
  • May 2024
  • 130 Pages
  • Global
From
Non-Small Cell Lung Cancer - Market Insight, Epidemiology, and Market Forecast -2034 - Product Thumbnail Image

Non-Small Cell Lung Cancer - Market Insight, Epidemiology, and Market Forecast -2034

  • Report
  • January 2025
  • 880 Pages
  • Global
From
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Thumbnail Image

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • June 2024
  • 200 Pages
  • Global
From
Non-Small Cell Lung Cancer (NSCLC) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Thumbnail Image

Non-Small Cell Lung Cancer (NSCLC) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • February 2024
  • 110 Pages
  • Global
From
  • 6 Results (Page 1 of 1)
Loading Indicator

Dacomitinib is a type of lung cancer drug used to treat non-small cell lung cancer (NSCLC). It is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Dacomitinib is used in combination with other drugs to treat NSCLC that has spread to other parts of the body or that has not responded to other treatments. It is also used to treat NSCLC that has a certain type of genetic mutation. Common side effects of dacomitinib include fatigue, nausea, diarrhea, and rash. Several companies are involved in the dacomitinib market, including Pfizer, AstraZeneca, and Novartis. These companies are involved in the research, development, and marketing of dacomitinib and other lung cancer drugs. Show Less Read more